Pamidronate

Pamidronate treats high blood calcium levels and certain bone problems including metastases/lesions that occur in some forms of cancer, in addition to being used in the treatment of a certain type of bone disease (Paget's disease) that causes abnormal and weak bones. It prevents bone loss, and treat osteoporosis, and strengthens bone in Paget's disease, to prevent bone loss due to steroid use. It is also used in certain cancers with a high propensity to the bone, such as multiple myeloma. It sequesters calcium in bone, so it can also treat high calcium levels, and finally being used as an experimental treatment of the bone disorder osteogenesis imperfect and complex regional pain syndrome. Pamidronate is a bisphosphonate and slows the release of calcium from bones to lower blood calcium levels. This lowers the risk of broken bones in addition to reducing bone pain. Pamidronate is sold under the brand names Aredia, Aredronet, Biodronate among others. Aesgen, Inc. filed the first patent for the preparation of Pamidronate in 1998 and has been on sale around the world since then. The current assignee for a new type of formulation has been given to Mayne Pharma Pty.

Dosage Forms & Strengths

Pamidronate is sold as a powder for reconstitution in 30mg and injection solution as disodium in 3mg/mL, 6mg/mL and 9mg/mL strengths. In the treatment of Hypercalcemia of Malignancy, in moderate cases, the dose is 60-90 mg, single-dose, given through an IV infusion over 2-24 hours, and in Severe hypercalcemia, this is increased to 90 mg, single- dose, given through an IV infusion over 2-24 hours. In the treatment of Paget’s Disease, the the dose is 30 mg, given through an IV infused over 4 hours, for 3 consecutive days, totaling a the dose of 90 mg. the dose in the case of Osteolytic Bone Metastases of Breast Cancer is 90 mg, given through an IV infusion over 2 hours, for a course duration of 3 to 4 weeks, and in treating Osteolytic Bone Lesions of Multiple Myeloma, the dose is set at 90 mg, given through an IV infusion over 4 hours for a month. For prophylaxis of Androgen deprivation- induced Osteoporosis, the dose is 60 mg, given through an IV infusion over 2 hours, every 3 months or 90 mg administered once over 3-4 hours.

The price of Pamidronate

In India, the consumer pays USD 25 for or 1 vial of 10mg supply for an injection.

How does it work?

Pamidronate, a bisphosphonate is injected into the bone there it binds to hydroxyapatite. osteoclasts lead Bone resorption causes local acidification. This releases bisphosphonate, which when taken into osteoclast by fluid-phase endocytosis. Endocytic vesicles get acidified, which results in the release of bisphosphonates into the cytosol of osteoclasts where they act. Osteoclasts mediate resorption of bone by bind to the bone they form podosomes, ring structures of F-actin. This disruption of the podosomes causes osteoclasts to detach from bones, the final result is the prevention of bone resorption.

Finding Pamidronate Manufacturers and Suppliers

The best way to find and gain access to Pamidronate manufacturers and Pamidronate suppliers are to make through Pipelinepharma's global B2B online marketplace for medicines and other pharmaceuticals. Normally, finding trusted manufacturers and supplies of specific drugs like Pamidronate can be a time-consuming challenge, but with Pipelinepharma's simple search engine and the network of proven partners, the whole process becomes a lot easier. All you need to do to get started is to make use of our integrated search engine and start looking for suppliers or manufacturers of Pamidronate to work with. You can fine-tune your search results using various filters too, letting you search for Pamidronate from specific countries.